Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CDMO Famar and Active Biotech Ink Clinical Manufacturing Deal | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

CDMO Famar and Active Biotech Ink Clinical Manufacturing Deal

Will deliver clinical trial material of the newly developed eye-drop formulation of laquinimod.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Active Biotech AB has reached a manufacturing agreement with Famar Health Care Services Madrid SAU, a European provider of pharmaceutical manufacturing and development services. Famar will deliver clinical trial material of the newly developed eye-drop formulation of laquinimod.
 
The new formulation is developed by Active Biotech together with Leukocare AG, a biotechnology company from Munich, Germany, specialized in pharmaceutical formulation development. The formulation will be studied for the treatment of non-infectious non-anterior uveitis, which is an orphan disease and a serious, sight-threatening condition.
 
The agreement with Famar includes clinical trial material for dosing in clinical Phase I and II studies for the treatment of ophthalmic disorders. Famar R&D will provide process development, scale-up, supply of material for pre-clinical local tolerance studies and clinical grade material for use in the clinical studies.
 
The project has been initiated, and Active Biotech is aiming to start a clinical safety study in H2 2021. Active Biotech also plans to initiate a proof-of-principle study with oral laquinimod in uveitis patients in 2021.
 
“We are very excited with this collaboration with Famar, which makes it possible for us to start the first clinical safety study with this newly developed eye-drop formulation of laquinimod later this year,” said Helén Tuvesson, chief executive officer, Active Biotech.
 
Ian Cooper, chief executive officer, Famar, said, “We welcome this new collaboration with Active Biotech with excitement. Famar’s development service activity is a key element in Famar’s strategy to further develop and expand its health care services and customers’ portfolio.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics